Brian Stephenson Purchases 831 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 831 shares of the stock in a transaction on Monday, June 29th. The stock was purchased at an average cost of $23.34 per share, for a total transaction of $19,395.54. Following the acquisition, the chief financial officer owned 33,885 shares of the company’s stock, valued at $790,875.90. This trade represents a 2.51% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ:FTH opened at $22.92 on Friday. The stock has a market capitalization of $30.76 million, a price-to-earnings ratio of -0.16 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 52-week low of $6.32 and a 52-week high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. As a group, equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on FTH shares. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Finally, BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.